Press coverage about Axovant Sciences (NASDAQ:AXON) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.9174818756135 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of analysts have commented on the company. Chardan Capital reissued a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a report on Saturday, September 23rd. BidaskClub upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 23rd. Oppenheimer downgraded Axovant Sciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 26th. JMP Securities restated an “outperform” rating and issued a $19.00 price target (down from $36.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies downgraded Axovant Sciences from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $32.00 to $9.00 in a research note on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $14.13.
Axovant Sciences (NASDAQ AXON) opened at $5.40 on Monday. Axovant Sciences has a 52-week low of $4.60 and a 52-week high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.